The announcement is reproduced below in a more legible format....

The announcement is reproduced below in a more legible format.

Approx AU$300M to be raised from 17M TLX shares issued, representing 4.8% voting dilution but without value dilution to Aus shareholders.

I wonder what the plans are for the spare AU$300M.

___________________
Telix Announces Launch of Proposed Initial Public Offering in the United States

MELBOURNE, Australia, June 05, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (the "Company" or "Telix") today announces the launch of its initial public offering in the United States (the "Offering") of 17,000,000 American Depositary Shares ("ADSs"), each representing one ordinary share in Telix. The target size of the Offering is US$200million in gross proceeds.

In addition, Telix expects to grant the Underwriters (as defined below) a 30-day option to purchase up to an additional 15% of the number of ADSs sold in the Offering at the initial public offering price, less underwriting discounts and commissions.

All ADSs to be issued in the Offering will be offered by Telix. Jefferies, Morgan Stanley, Truist Securities and William Blair are acting as joint book-running managers for the Offering (collectively, the Underwriters).

Telix has applied to list its ADSs on the Nasdaq Global Market (Nasdaq) under the ticker symbol "TLX". Telix's ordinary shares are listed, and upon the completing of the Offering, will continue to trade on the Australian Securities Exchange (ASX) under the symbol "TLX". The Offering is being made only by means of a prospectus under the U.S. Securities Act of 1933, as amended.

Copies of the preliminary prospectus relating to and describing the terms of the Offering may be obtained, when available, from

(i) Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, or by telephone at (877) 821-7388, or by email at [email protected]; or

(ii) Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or by email at [email protected]; or

(iii) Trust Securities, Inc., Attention: Prospectus Department, 3333 Peachtree Road NE, 9th floor, Atlanta, GA 30326, or by telephone at (800) 685-4786, or by email at [email protected]; or

(iv) William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, or by telephone at (800) 621-0687, or by email at [email protected].

Australian investors are only eligible to invest under the prospectus if they are exempt from disclosure (for example, as sophisticated or professional investors) under the Corporations Act 2001 (Cth).

A registration statement relating to the securities referred to herein has been filed with the Securities and Exchange Commission but has not yet become effective.

These securities may not be sold, nor may offers to buy these securities be accepted, prior to the time the registration statement becomes effective.

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

As disclosed in the registration statement, the Underwriters may purchase and sell ADSs in the open market, including to cover over-allotments in connection with market stabilization activities in relation to the Offering.